Oxford Cannabinoid Technologies Holdings PLC - cannabinoid medicines-focused pharmaceutical firm - Announces that the Medicines & Healthcare Products Regulatory Agency and the Wales Research Ethics Committee have approved the company’s combined Phase I clinical trial application for OCTP’s lead drug candidate, OCT461201. This Phase I first-in-human clinical trial is being conducted in the UK in healthy volunteers, with a single ascending dose protocol. Participant enrolment will begin immediately, and the trial is expected to be completed during the third quarter. The trial is being funded entirely from OCTP’s existing resources.

Current stock price: 1.28 pence, up 2.4% in London on Wednesday

12-month change: up 35%

Copyright 2023 Alliance News Ltd. All Rights Reserved.